Celon Pharma (CLN) Q4 2025 earnings summary

Executive summary

• Consolidated revenues reached PLN 244M in FY2025, up 17.9% year-over-year, driven by both Generics and Innovation segments, with strong export and grant income growth.

• EBITDA rose 42.3% to PLN 21.4M, with the Generics segment maintaining high profitability and the Innovation segment investing heavily in R&D.

• Major capital investment in a new state-of-the-art pen injector facility in Slovakia, targeting the rapidly growing GLP-1 market.

Financial highlights

• Generics segment revenue grew 15.3% year-over-year to PLN 206M; domestic sales up 13.7%, exports up 20.7%.

• Innovation segment revenue increased 34.3% to PLN 38M, with grant income up 25.9%.

• EBITDA margin for Generics improved to 36.8% (from 31.3%); Innovation EBITDA margin remained negative at -143.4%.

• Net cash flows for FY2025 were -PLN 8M, reflecting intensified capital investment.

Outlook and guidance

• Commercial revenues from Innovation assets expected only after regulatory approval and successful partnering.

• New Slovakia facility to enable entry into the GLP-1 pen injector market, with first commercial output targeted for late 2026.